Check J H, Goldberg B B, Kurtz A, Adelson H G, Rankin A
Int J Fertil. 1984;29(3):156-8.
In some series the most appropriate therapy for luteal phase defects is supplemental progesterone in the luteal phase. Clomiphene's efficacy is more controversial since in one series only 8% achieved a successful pregnancy versus 45% in another study. Pelvic sonography was used to evaluate follicular development and release of the ovum in 50 infertile women with luteal phase defects. The results showed that only 40% had "pure" luteal phase defects whereas 52% had immature follicles and 8% had unruptured follicles. Sixty-two percent of the patients had previous therapy for a luteal phase defect and failed to conceive. Sixty-eight percent of this group did conceive when ultrasound was used to determine the appropriate therapy. Thus ultrasound can be employed to determine if the women with a luteal phase defect should be treated with a fertility drug, e.g., clomiphene or just with luteal phase progesterone support. Supplemental progesterone might still be needed with clomiphene based on repeat endometrial biopsy results.
在一些研究系列中，黄体期缺陷最适宜的治疗方法是在黄体期补充黄体酮。克罗米芬的疗效更具争议性，因为在一个研究系列中只有8%成功怀孕，而在另一项研究中这一比例为45%。对50例患有黄体期缺陷的不孕妇女，采用盆腔超声检查来评估卵泡发育及卵子排出情况。结果显示，只有40%存在“单纯”的黄体期缺陷，而52%有未成熟卵泡，8%有卵泡未破裂。62%的患者曾接受过黄体期缺陷治疗但未受孕。当使用超声来确定合适的治疗方法时，该组中有68%确实受孕了。因此，超声可用于确定患有黄体期缺陷的女性是应该用生育药物（如克罗米芬）治疗，还是仅给予黄体期黄体酮支持。根据重复子宫内膜活检结果，使用克罗米芬时可能仍需要补充黄体酮。
